Hualan Biological Bacterin Inc.

Group AC Meningococcal Polysaccharide Vaccine of Hualan Bio logical Bacterin Co., Ltd Passing GMP On March 26, 2018, Hualan Biological Bacterin Co., Ltd received production licenses of Group AC Meningococcal Polysaccharide Vaccine issued by CFDA. On May 8, 2018, Hualan Biological Bacterin Co., Ltd got GMP Certificate issued by CFDA, the certificate number is HA20180019, the certification scope is Group AC Meningococcal Polysaccharide Vaccine, valid until April 27, 2023. Then the company is approved to produce and sell the vaccines offically.                                           http://english.hualanbio.com/information/shownews.php?lang=en& id=141

From April 19-21, 2018, t he 6th CSITF, China (Shanghai) International Technology Fair was held at Shanghai World Expo Exhibition & Convention Center. The CSITF consists of 4 special subjects, intelligent manufacturing, energy conservation and environmental protection, new generation information technology, biological medicine. As the leader enterprise in biological medicine industry, Hualan Bio is honor to be invited to attend the exhibition and gets good achievements. http://english.hualanbio.com/

Lot Release Annual Report o f Biological Products i n 2016:   Albumin a nd Coagulation Factor VIII we re Still i n Short Supply In July 4 th   , 2 017,   official website  of   CFDA issued the  Lot Release  Annual Report of Biological Products in 2016, which was compiled by National Institutes for Food and Drug Control. This report was the most authoritative source of data to comprehend the market demand and supply of domestic vaccines and plasma products. Hualan Biological Human Albumin In 2016, release 3949 batches of vaccines and approximately  646 million doses ; 4025 batches  of   plasma  products and approximately  59 . 278 million vial s; 836 batches  of blood screening reagent and about  878 million doses . At present, the lot released vaccine s  and blood screening reagents   are mainly made in China , while the imported products are less than 5 %. As for the plasma  products ,  ...

Hualan Bio Attending the 2017 CPhI Worldwide Exhibition From October 24-26, 2017, 2017 CPhI Worldwide Exhibition was held in Frankfurt. As the leading enterprises in domestic biological pharmaceutical industry, with the support of HulanBiological Engineering Inc . , Hualan Biological Bacterin Co., Ltd. attended the exhibition. Hualan Biological in 2017 CPhI Frankfurt Exhibition In the exhibition, the customers from Columbia, Pakistan, Turkey and other countries showed great interest in our plasma and vaccine products, such as Human Albumin, IVIG , Inactivated Influenza Vaccine (Split virion), Inactivated, Meningococcal Polysaccharide Vaccine Group ACYW135, and etc. which could extend Hualan Bio's oversea business, and most of them were interested to visit Hualan Bio's facilities. For next step, Hualan Bio will strengthen the oversea business cooperation and build a new cooperation platform to all cooperation customers. The Booth of Hualan Biolgocal in 2017 CPHI F...

Novel Influenza Vaccine -The Effect of Vaccination Once Last Ten Years   WHO will publish a list of most possible occurred influenza virus in this season every year, then the pharmaceutical manufacturer will development the most needed vaccine according to the list. But there are always unexpected events, so that many influenza vaccines will be inefficient in this year. The protein on the surface of virus is mutagenic most likely, while the protein inside the cell is not mutagenic frequently. In this case, we should provide more effective vaccine against the inner protein. Influenza Vaccine of Hualan Bio The vaccine developed by Cornell University is similar with this vaccine, and the aim is for Matrix-2 (M2) which is invariant protein found in flu strain of people, avian, and pig.  The researchers adopt two kinds bird flu genes sequences, and one is from pig, the other is from people. Both contain M2, and the researchers merge them into drug, then load the antigen...

Hualan Biological Flu Vaccine Exporting to Ukraine Recently, Hualan Biological Bacterin Co., Ltd signed a sales contract with Ukrainian customers for 200,000 person’s influenza vaccines. All the vaccines had finished the export process and been delivered safely to Ukraine. Ukraine is located in Eastern Europe, with a population of about 4 million, more than 300 people died due to the flu epidemic in 2016. This time, the imported flu vaccine from Hualan Biological will help the Ukrainian to prevent and control the flu disease, and promote the recognition of Hualan Biological flu vaccine in Eastern European countries. Hualan Biological Flu Vaccine Exporting to Ukraine 

On September 8, 2017, Hualan Biological Bacterin Co. LTD received a purchase order from the UNICEF for Influenza Vaccine (Split Virion) Inactivated , highlighting the endorsement to Hualan brand and product quality by the UNICEF Supply Division, which will facilitate the cooperation between Hualan and the relevant procurement agencies of the United Nations, and benefit the participation of Hualan products in international market and promote the internationalization of Hualan products. Hualan Biological Receiving Influenza Vaccine Order from UNICEF The United Nations Children's Fund ( UNICEF ) is a voluntary fund agency for the long-term humanitarian and development assistance of mothers and children in developing countries, which is established in December 1946, and for more than 70 years, the UNICEF has fought for rights of every child in 190 countries around the world. At present, UNICEF is the world's largest purchaser of vaccines, which procures vaccine on b...